Ram E, Lavee J, Tenenbaum A, et al. - Given that patients who undergo heart transplantation (HT) exhibit a high prevalence of type 2 diabetes mellitus (T2D), researchers examined the link between metformin therapy and cardiovascular outcomes following HT. Participants included 103 patients with T2D who had undergone HT between 1994 and 2018 and were prospectively observed. Metformin was used to treat 55 HT patients (53%) in the cohort. Findings revealed an independent link between metformin therapy and a significant decrease in the long-term risk for cardiac allograft vasculopathy (CAV) and the combined end-point of CAV or cardiovascular mortality post-HT in diabetic HT patients.